Genotype-by-environment interactions in chronic back pain
- PMID: 37080360
- DOI: 10.1016/j.spinee.2023.04.009
Genotype-by-environment interactions in chronic back pain
Abstract
Background context: Chronic back pain (CBP) is a common debilitating condition with substantial societal impact. While understanding genotype-by-environment (GxE) interactions may be crucial to achieving the goals of personalized medicine, there are few large-scale studies investigating this topic for CBP. None of them systematically explore multiple CBP risk factors.
Purpose: To estimate the extent to which genetic effects on CBP are modified by known demographic and clinical risk factors.
Research design: Case-control study, genome-wide GxE interaction study.
Patient sample: Data on up to 331,610 unrelated participants (57,881 CBP cases and 273,729 controls) from the UK Biobank cohort were used. UK Biobank is a prospective cohort with collected deep genetic and phenotypic data on approximately 500,000 individuals across the UK.
Outcome measures: Self-reported chronic back pain.
Methods: We applied a whole-genome approach to estimate the proportion of phenotypic variance explained by interactions between genotype and 12 known risk factors. We also analyzed if effects of common single-nucleotide polymorphisms on CBP are changed in presence of known risk factors.
Results: The results indicate a modest, if any, modification of genetic effects by examined risk factors in CBP. Our estimates suggest that detecting such weak effects would require a sample size of millions of individuals.
Conclusions: The GxE interactions with examined common risk factors for CBP are either weak or absent. Interactions of such magnitude are unlikely to have the potential to inform and influence treatment strategies. Risk estimation models may use common genetic variation and the considered risk factors as independent predictors, without accounting for GxE.
Keywords: Chronic back pain; Genotype-by-environment interactions; Risk factors.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS).Cochrane Database Syst Rev. 2025 Jun 10;6(6):CD011330. doi: 10.1002/14651858.CD011330.pub2. Cochrane Database Syst Rev. 2025. PMID: 40492482 Review.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
-
Omega-3 fatty acids for depression in adults.Cochrane Database Syst Rev. 2015 Nov 5;2015(11):CD004692. doi: 10.1002/14651858.CD004692.pub4. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2021 Nov 24;11:CD004692. doi: 10.1002/14651858.CD004692.pub5. PMID: 26537796 Free PMC article. Updated.
Cited by
-
Development and Replication of a Genome-Wide Polygenic Risk Score for Chronic Back Pain.J Pers Med. 2023 Jun 10;13(6):977. doi: 10.3390/jpm13060977. J Pers Med. 2023. PMID: 37373966 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical